Episode 231
Reden wir über Brustkrebs! Experten diskutieren aktuelle CDK4/6-Daten und ihre klinische Anwendung
November 13, 202422m 45s
Audio is streamed directly from the publisher (audio.podigee-cdn.net) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Zum Weiterlesen:
- Loibl S et al. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024, 35(2):159-182
https://www.annalsofoncology.org/article/S0923-7534(23)05104-9/fulltext
- Kalinsky K et al. Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. J Clin Oncology 2024,42(17suppl): LBA1001
https://ascopubs.org/doi/10.1200/JCO.2024.42.17_suppl.LBA1001
- FKI Verzenios (Abemaciclib)
Topics
OnkologieGesundheitMedizinBrustkrebs